9 Meters Biopharma is a clinical-stage company focusing on the treatments for people with rare digestive diseases, gastrointestinal (GI) conditions with unmet needs, and debilitating disorders in which the biology of the gut is a contributing factor. Co. is deveoping its primary product candidate, vurolenatide for the treatment of SBS, as well as NM-136 for rare obesity disorders. Co. is also developing NM-003 and NM-102 for the treatment of undisclosed rare debilitating digestive diseases with unmet needs and larazotide for the treatment of Multi-system Inflammatory Syndrome through a collaboration with the European Biomedical Research Institute of Salerno, Italy. We show 14 historical shares outstanding datapoints in our NMTR shares outstanding history coverage, used to compute NMTR market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing NMTR market cap history over the course of time is important for investors
interested in comparing NMTR's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of NMTR versus a peer is one thing; comparing
NMTR market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like NMTR can fluctuate over the course of history.
With this page we aim to empower investors researching NMTR by allowing them to research the NMTR market cap history. |
Free NMTR Email Alerts:
Video: The Importance of Market Cap
